Literature DB >> 17513062

Prostate postbrachytherapy seed distribution: comparison of high-resolution, contrast-enhanced, T1- and T2-weighted endorectal magnetic resonance imaging versus computed tomography: initial experience.

B Nicolas Bloch1, Robert E Lenkinski, Thomas H Helbich, Long Ngo, Renee Oismueller, Silvia Jaromi, Klaus Kubin, Robert Hawliczek, Irving D Kaplan, Neil M Rofsky.   

Abstract

PURPOSE: To compare contrast-enhanced, T1-weighted, three-dimensional magnetic resonance imaging (CEMR) and T2-weighted magnetic resonance imaging (T2MR) with computed tomography (CT) for prostate brachytherapy seed location for dosimetric calculations. METHODS AND MATERIALS: Postbrachytherapy prostate MRI was performed on a 1.5 Tesla unit with combined surface and endorectal coils in 13 patients. Both CEMR and T2MR used a section thickness of 3 mm. Spiral CT used a section thickness of 5 mm with a pitch factor of 1.5. All images were obtained in the transverse plane. Two readers using CT and MR imaging assessed brachytherapy seed distribution independently. The dependency of data read by both readers for a specific subject was assessed with a linear mixed effects model.
RESULTS: The mean percentage (+/- standard deviation) values of the readers for seed detection and location are presented. Of 1205 implanted seeds, CEMR, T2MR, and CT detected 91.5% +/- 4.8%, 78.5% +/- 8.5%, and 96.1% +/- 2.3%, respectively, with 11.8% +/- 4.5%, 8.5% +/- 3.5%, 1.9% +/- 1.0% extracapsular, respectively. Assignment to periprostatic structures was not possible with CT. Periprostatic seed assignments for CEMR and T2MR, respectively, were as follows: neurovascular bundle, 3.5% +/- 1.6% and 2.1% +/- 0.9%; seminal vesicles, 0.9% +/- 1.8% and 0.3% +/- 0.7%; periurethral, 7.1% +/- 3.3% and 5.8% +/- 2.9%; penile bulb, 0.6% +/- 0.8% and 0.3% +/- 0.6%; Denonvillier's Fascia/rectal wall, 0.5% +/- 0.6% and 0%; and urinary bladder, 0.1% +/- 0.3% and 0%. Data dependency analysis showed statistical significance for the type of imaging but not for reader identification.
CONCLUSION: Both enumeration and localization of implanted seeds are readily accomplished with CEMR. Calculations with MRI dosimetry do not require CT data. Dose determinations to specific extracapsular sites can be obtained with MRI but not with CT.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17513062     DOI: 10.1016/j.ijrobp.2007.02.039

Source DB:  PubMed          Journal:  Int J Radiat Oncol Biol Phys        ISSN: 0360-3016            Impact factor:   7.038


  10 in total

1.  Multiparametric MRI of the prostate at 3 T: limited value of 3D (1)H-MR spectroscopy as a fourth parameter.

Authors:  Stephan H Polanec; Katja Pinker-Domenig; Peter Brader; Dietmar Georg; Shahrokh Shariat; Claudio Spick; Martin Susani; Thomas H Helbich; Pascal A Baltzer
Journal:  World J Urol       Date:  2015-09-25       Impact factor: 4.226

2.  Angle-dependent ultrasonic detection and imaging of brachytherapy seeds using singular spectrum analysis.

Authors:  Jonathan Mamou; Sarayu Ramachandran; Ernest J Feleppa
Journal:  J Acoust Soc Am       Date:  2008-04       Impact factor: 1.840

3.  Permanent prostate brachytherapy postimplant magnetic resonance imaging dosimetry using positive contrast magnetic resonance imaging markers.

Authors:  Geoffrey V Martin; Thomas J Pugh; Usama Mahmood; Rajat J Kudchadker; Jihong Wang; Teresa L Bruno; Tharakeswara Bathala; Pierre Blanchard; Steven J Frank
Journal:  Brachytherapy       Date:  2017-05-10       Impact factor: 2.362

4.  [Multiparametric prostate MRI for follow-up monitoring after radiation therapy].

Authors:  A M Weidner; D J Dinter; M Bohrer; M Sertdemir; D Hausmann; F Wenz; S O Schoenberg
Journal:  Radiologe       Date:  2012-03       Impact factor: 0.635

5.  [Diagnose importance of multiparametric magnetic resonance tomography for prostate cancer].

Authors:  B J Fueger; T H Helbich; M Schernthaner; S Zbýn; H G Linhart; A Stiglbauer; A Doan; K Pinker; G Heinz; A R Padhani; P Brader
Journal:  Radiologe       Date:  2011-11       Impact factor: 0.635

6.  The role of magnetic resonance imaging (MRI) in prostate cancer imaging and staging at 1.5 and 3 Tesla: the Beth Israel Deaconess Medical Center (BIDMC) approach.

Authors:  B Nicolas Bloch; Robert E Lenkinski; Neil M Rofsky
Journal:  Cancer Biomark       Date:  2008       Impact factor: 4.388

Review 7.  Imaging of prostate cancer local recurrences: why and how?

Authors:  Olivier Rouvière; Thierry Vitry; Denis Lyonnet
Journal:  Eur Radiol       Date:  2009-11-17       Impact factor: 5.315

8.  Improved dosimetry in prostate brachytherapy using high resolution contrast enhanced magnetic resonance imaging: a feasibility study.

Authors:  Karen Buch; Tye Morancy; Irving Kaplan; Muhammad M Qureshi; Ariel E Hirsch; Neil M Rofksy; Edward Holupka; Renee Oismueller; Robert Hawliczek; Thomas H Helbich; B Nicolas Bloch
Journal:  J Contemp Brachytherapy       Date:  2014-10-28

9.  A new two-step accurate CT-MRI fusion technique for post-implant prostate cancer.

Authors:  Hiroaki Kunogi; Hidehiro Hojo; Yoshiaki Wakumoto; Anneyuko I Saito; Satoshi Ishikura; Yuki Yamashiro; Ryouhei Kuwatsuru; Keisuke Sasai
Journal:  J Contemp Brachytherapy       Date:  2015-04-30

10.  Automated estimation of number of implanted iodine-125 seeds for prostate brachytherapy based on two-view analysis of pelvic radiographs.

Authors:  Hidemichi Kawata; Hidetaka Arimura; Hiroaki Suefuji; Sunao Ohkura; Yoshifumi Saida; Kazutaka Nashiki; Kazuya Hayashida; Tomomi Kawahara; Ayumu Ohishi; Naofumi Hayabuchi
Journal:  J Radiat Res       Date:  2012-07-05       Impact factor: 2.724

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.